Fmr LLC Has $83.64 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Fmr LLC decreased its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 12.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,900,254 shares of the company’s stock after selling 399,536 shares during the period. Fmr LLC owned 2.33% of Apellis Pharmaceuticals worth $83,643,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Tidal Investments LLC acquired a new stake in Apellis Pharmaceuticals in the first quarter worth about $266,000. Comerica Bank lifted its holdings in Apellis Pharmaceuticals by 500.7% in the first quarter. Comerica Bank now owns 8,163 shares of the company’s stock valued at $480,000 after buying an additional 6,804 shares during the period. CWM LLC boosted its stake in Apellis Pharmaceuticals by 299.9% in the second quarter. CWM LLC now owns 4,151 shares of the company’s stock valued at $159,000 after acquiring an additional 3,113 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Apellis Pharmaceuticals by 6.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 345,195 shares of the company’s stock worth $13,242,000 after acquiring an additional 22,273 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Apellis Pharmaceuticals by 15.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,614 shares of the company’s stock valued at $752,000 after acquiring an additional 2,635 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Wall Street Analysts Forecast Growth

APLS has been the topic of a number of recent analyst reports. William Blair began coverage on Apellis Pharmaceuticals in a report on Wednesday, October 16th. They set an “outperform” rating on the stock. HC Wainwright decreased their price objective on shares of Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Bank of America cut their target price on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Mizuho decreased their price target on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a report on Thursday, October 24th. Finally, Oppenheimer dropped their price objective on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $49.94.

Apellis Pharmaceuticals Trading Down 2.0 %

NASDAQ APLS opened at $33.45 on Friday. The stock has a 50-day moving average of $28.99 and a 200-day moving average of $35.14. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 1-year low of $24.34 and a 1-year high of $73.80. The firm has a market cap of $4.16 billion, a PE ratio of -16.48 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million for the quarter, compared to analysts’ expectations of $200.00 million. During the same quarter in the prior year, the company posted ($1.17) earnings per share. The business’s revenue for the quarter was up 78.3% on a year-over-year basis. As a group, sell-side analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.72 EPS for the current year.

Insider Transactions at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. This represents a 27.01 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).